Download MendeleyDiscovery of Potent and Selective Covalent Inhibitors of HER2 WT and HER2 YVMA .
Hicken, E.J., Brown, K., Dwulet, N.C., Gaudino, J.J., Hansen, E.P., Hartley, D.P., Kowalski, J.P., Laird, E.R., Lazzara, N.C., Li, B., Mou, T.C., Mutryn, M.F., Oko, L., Pajk, S., Pipal, R.W., Rosen, R.Z., Shelp, R., Singh, A., Wang, J., Wise, C.E., Wong, C., Wong, J.Y.(2024) J Med Chem 67: 9759-9771
- PubMed: 38820338
- DOI: https://doi.org/10.1021/acs.jmedchem.4c00978
- Primary Citation of Related Structures:
8U8X - PubMed Abstract:
HER2 overexpression and amplification have been identified as oncogenic drivers, and the development of therapies to treat tumors harboring these markers has received considerable attention. Activation of HER2 signaling and subsequent cell growth can also be induced by HER2 mutations, including the common YVMA insertion in exon 20 within the kinase domain. Enhertu is currently the only approved treatment for HER2 mutant tumors in NSCLC. TKIs tested in this space have suffered from off-target activity, primarily due to EGFR WT inhibition or attenuated activity against HER2 mutants. The goal of this work was to identify a TKI that would provide robust inhibition of oncogenic HER2 WT and HER2 mutants while sparing EGFR WT activity. Herein, we describe the development of a potent, covalent inhibitor of HER2 WT and the YVMA insertion mutant while providing oral bioavailability and avoiding the inhibition of EGFR WT .
Organizational Affiliation:
Pfizer Boulder Research and Development, Boulder, Colorado 80301, United States.
